Stephens Issues Positive Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective boosted by equities research analysts at Stephens from $7.00 to $9.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Stephens’ target price indicates a potential upside of 3.93% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Piper Sandler dropped their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Citigroup boosted their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday. Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. boosted their price target on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.71.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $8.66 on Thursday. The company has a market capitalization of $526.96 million, a P/E ratio of -6.41 and a beta of 1.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41. The company has a fifty day moving average of $8.13 and a 200-day moving average of $7.20.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.22) earnings per share. As a group, equities research analysts predict that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is currently owned by company insiders.

Institutional Trading of Health Catalyst

Several institutional investors have recently bought and sold shares of HCAT. Millrace Asset Group Inc. bought a new position in shares of Health Catalyst in the third quarter worth approximately $1,568,000. Primecap Management Co. CA lifted its position in Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after acquiring an additional 25,000 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Health Catalyst during the 3rd quarter valued at $145,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Health Catalyst by 118.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 131,532 shares of the company’s stock worth $1,071,000 after purchasing an additional 71,201 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth $34,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.